Brief: Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda
18/10/2025 15:30
Oct 18 (Reuters) - PFIZER: CO & ASTELLAS ANNOUNCE POSITIVE RESULTS FROM PHASE 3EV-303 CLINICAL TRIAL FOR PADCEV IN COMBINATION WITH KEYTRUDA PFIZER: PADCEV PLUS KEYTRUDA CUTS RISK OF RECURRENCE, PROGRESSION OR DEATH BY 60% & RISK OF DEATH BY 50% FOR CERTAIN PATIENTS WITH BLADDER CANCER Source text: [ID:] Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)